Q2 2024 Earnings Summary
- Significant Adjusted EBITDA Growth Expected in 2025: Fortrea anticipates a 30-40% increase in adjusted EBITDA in 2025, aiming for an adjusted EBITDA margin in the 11% to 12% range. This growth is expected to come from both gross margin improvements through operational efficiencies and reductions in SG&A expenses after fully exiting the TSA agreements with its former parent company.
- Strong Cost Management Leading to Improved Margins: The company is aggressively implementing cost reduction initiatives, including restructuring programs that started in the second quarter and continued into the third quarter. Additional benefits from these initiatives are expected in Q3 and Q4, contributing to margin improvements and increased profitability.
- Robust Pipeline with Increased Large Pharma Opportunities: Fortrea has a strong pipeline for the second half of the year, with more large pharma opportunities that are more consistent and predictable in their scheduling. The company expects to achieve an average 1.2 book-to-bill ratio across Q3 and Q4, which should drive future revenue growth.
- Fortrea lowered its full-year 2024 revenue guidance to a midpoint of $2.725 billion, reflecting a decline of around 4% versus 2023, due to lower-than-expected new business awards and declining pass-through revenues. This indicates challenges in revenue growth and potential market demand issues.
- The company reduced its adjusted EBITDA margin target for 2025 to 11%-12%, down from the previously targeted 13%, highlighting pressure on profitability and potential difficulties in cost management despite restructuring efforts.
- Fortrea experienced two consecutive quarters of lower-than-expected book-to-bill ratios, with Q2 coming in just under 1 versus a target of 1.2, due to difficulties in predicting contract timing with biotech clients. This raises concerns about the company's ability to convert its pipeline into revenue and its reliance on the unpredictable biotech sector.
-
Bookings Weakness and Pipeline Confidence
Q: Why was bookings light despite a strong pipeline?
A: We faced delays in biotech contracts due to slower decision-making, but our pipeline remains strong with increased large pharma opportunities, giving us confidence for higher book-to-bill ratios in the second half. -
Achieving 2025 Margin Targets and Book-to-Bill Dependence
Q: Can you hit 2025 margin targets without 1.2 book-to-bill?
A: Achieving our 11–12% EBITDA margins in 2025 relies on maintaining a 1.2x book-to-bill in the second half; while slight shortfalls might allow some margin expansion, hitting that ratio is crucial for our targets. -
Biotech Decision Delays Impacting Revenue
Q: Are biotech delays affecting revenues?
A: Yes, biotech clients are taking longer in decision-making due to increased internal reviews, causing delays in contracting and impacting short-term bookings and revenue conversion. -
Cost Savings and Margin Expansion Plans
Q: How will you expand margins?
A: We plan to drive margin expansion through equal parts productivity improvements in project delivery and SG&A reductions, especially after exiting TSAs, with ongoing tight cost management. -
Pass-Through Revenue Decline and Service Fee Growth
Q: Why is pass-through revenue declining?
A: Pass-through revenues are moderating due to fluctuations in biomarker studies, while service fee revenues are up mid-single digits, key for improving adjusted EBITDA. -
Pricing Environment in Pharma and Biotech
Q: How is the pricing environment?
A: Biotech pricing remains consistent with good market rates; in large pharma, full-service outsourcing sees reasonable pricing, though FSP deals are highly competitive with some competitors lowering prices. -
Spin-Related Costs and Impact on Earnings
Q: Why did spin-related costs triple in Q2?
A: Spin-related costs rose to $54 million, mainly due to heavy IT transitions accounting for about 80% of these costs; we expect lower but continued spend in Q3 and Q4. -
Employee Retention and Impact on Burn Rate
Q: Is turnover affecting project burn rate?
A: Employee attrition remains in line with industry norms and isn't significantly affecting our project burn rate or revenue recognition.
Research analysts covering Fortrea Holdings.